

Nausea/Vomiting	
ADULT	PEDIATRIC
BLS Procedures	
Maintain airway and position of comfort Administer oxygen as indicated	Maintain airway and position of comfort Administer oxygen as indicated
ALS Prior to Base Hospital Contact	
<p>Indications for Ondansetron:</p> <ol style="list-style-type: none"> Moderate to severe nausea or vomiting. Potential for airway compromise secondary to suspected/actual head injury when cervical immobilization is used. Prior to MS administration <ul style="list-style-type: none"> IV/IO access Cardiac Monitor Ondansetron <ul style="list-style-type: none"> PO – 4 mg ODT <ul style="list-style-type: none"> May repeat x 1 in 10 min IV/IM/IO – 4 mg <ul style="list-style-type: none"> May repeat x 1 in 10 min 	<p>Indications for Ondansetron:</p> <ol style="list-style-type: none"> Moderate to severe nausea or vomiting. Potential for airway compromise secondary to suspected/actual head injury when cervical immobilization is used. Prior to MS administration <ul style="list-style-type: none"> IV/IO access Cardiac Monitor <p>Ages 6 months up to 5 years</p> <ul style="list-style-type: none"> Ondansetron <ul style="list-style-type: none"> PO – 2 mg ODT IV/IM/IO – 0.1 mg/kg <p>Ages ≥ 5 Years</p> <ul style="list-style-type: none"> Ondansetron <ul style="list-style-type: none"> PO – 4 mg ODT IV/IM/IO – 0.1 mg/kg
Base Hospital Orders only	
Consult with ED Physician for further treatment measures	Consult with ED Physician for further treatment measures
<ul style="list-style-type: none"> The use of ondansetron should be avoided in patients with known congenital long QT syndrome Use caution in administration of ondansetron for patients with electrolyte imbalances, CHF, bradyarrhythmia, or patients taking medications known to prolong the QT interval 	

Effective Date: December 1, 2020
Next Review Date: October 31, 2022

Date Revised: October 8, 2020
Last Reviewed: October 8, 2020



VCEMS Medical Director